Wedbush Increases Kura Oncology (NASDAQ:KURA) Price Target to $36.00

Kura Oncology (NASDAQ:KURA) had its target price hoisted by equities researchers at Wedbush from $34.00 to $36.00 in a report released on Thursday,Benzinga reports. The firm currently has an “outperform” rating on the stock. Wedbush’s target price indicates a potential upside of 343.90% from the company’s current price.

Several other analysts have also weighed in on the stock. Stifel Nicolaus lowered shares of Kura Oncology from a “buy” rating to a “hold” rating and decreased their target price for the company from $26.00 to $19.00 in a research report on Monday, October 14th. Cantor Fitzgerald reissued an “overweight” rating on shares of Kura Oncology in a report on Monday, December 9th. Lifesci Capital raised Kura Oncology to a “strong-buy” rating in a research note on Tuesday, October 22nd. HC Wainwright boosted their target price on shares of Kura Oncology from $37.00 to $40.00 and gave the company a “buy” rating in a research note on Thursday. Finally, Scotiabank dropped their price objective on shares of Kura Oncology from $18.00 to $10.00 and set a “sector perform” rating for the company in a report on Wednesday, January 8th. One analyst has rated the stock with a sell rating, three have issued a hold rating, eight have issued a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $27.63.

Kura Oncology Stock Performance

Shares of Kura Oncology stock traded down $0.94 during midday trading on Thursday, hitting $8.11. The company had a trading volume of 2,276,215 shares, compared to its average volume of 1,760,466. The business’s 50 day simple moving average is $8.83 and its two-hundred day simple moving average is $15.16. Kura Oncology has a 1-year low of $6.98 and a 1-year high of $24.17. The company has a debt-to-equity ratio of 0.02, a current ratio of 11.47 and a quick ratio of 11.47. The stock has a market cap of $630.63 million, a PE ratio of -3.47 and a beta of 0.78.

Kura Oncology (NASDAQ:KURA) last issued its earnings results on Thursday, November 7th. The company reported ($0.63) EPS for the quarter, beating analysts’ consensus estimates of ($0.64) by $0.01. During the same period last year, the business earned ($0.50) earnings per share. As a group, equities analysts predict that Kura Oncology will post -2.44 EPS for the current fiscal year.

Insider Activity

In other Kura Oncology news, insider Mollie Leoni sold 4,963 shares of the company’s stock in a transaction dated Tuesday, January 28th. The shares were sold at an average price of $7.87, for a total transaction of $39,058.81. Following the transaction, the insider now directly owns 88,253 shares in the company, valued at approximately $694,551.11. This represents a 5.32 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, SVP Thomas James Doyle sold 4,949 shares of Kura Oncology stock in a transaction that occurred on Tuesday, January 28th. The stock was sold at an average price of $7.87, for a total transaction of $38,948.63. Following the sale, the senior vice president now owns 88,193 shares of the company’s stock, valued at approximately $694,078.91. This represents a 5.31 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 12,255 shares of company stock valued at $100,739 over the last three months. 5.50% of the stock is owned by insiders.

Hedge Funds Weigh In On Kura Oncology

Several large investors have recently bought and sold shares of KURA. Marshall Wace LLP bought a new stake in shares of Kura Oncology during the 2nd quarter valued at $541,000. AQR Capital Management LLC lifted its stake in Kura Oncology by 251.5% in the second quarter. AQR Capital Management LLC now owns 81,655 shares of the company’s stock valued at $1,681,000 after buying an additional 58,422 shares during the period. The Manufacturers Life Insurance Company raised its position in shares of Kura Oncology by 5.4% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 38,536 shares of the company’s stock valued at $793,000 after acquiring an additional 1,976 shares during the period. nVerses Capital LLC acquired a new position in shares of Kura Oncology in the third quarter valued at approximately $25,000. Finally, China Universal Asset Management Co. Ltd. lifted its holdings in shares of Kura Oncology by 64.7% in the third quarter. China Universal Asset Management Co. Ltd. now owns 14,739 shares of the company’s stock valued at $288,000 after purchasing an additional 5,788 shares in the last quarter.

Kura Oncology Company Profile

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.